AnaptysBio licenses imsidolimab to Vanda for $15M upfront; BLA/MAA prep underway

ANAPTYSBIO, INC

Anaptys receives $10M upfront and $5M for drug supply; eligible for up to $35M in milestones and 10% royalty on net sales.
Imsidolimab, an IL-36R antagonist, completed two global Phase 3 trials (GEMINI-1 and GEMINI-2) in Generalized Pustular Psoriasis.
Vanda plans to begin BLA and MAA submissions in the US and EU in 2025, leveraging its rare disease and anti-inflammatory expertise.
Positive Phase 3 data showed rapid disease clearance after single dose, maintained clear skin for at least 24 weeks with no safety signals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.